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Abstract
Background: The assembly and release of human immunodeficiency virus (HIV) particles from infected cells represent 
attractive, but not yet exploited targets for antiretroviral therapy. The availability of simple methods to measure the 
efficiency of these replication steps in tissue culture would facilitate the identification of host factors essential for these 
processes as well as the screening for lead compounds acting as specific inhibitors of particle formation. We describe 
here the development of a rapid cell based assay for quantification of human immunodeficiency virus type 1 (HIV-1) 
particle assembly and/or release.
Results: Using a fluorescently labelled HIV-derivative, which carries an eYFP domain within the main viral structural 
protein Gag in the complete viral protein context, the release of virus like particles could be monitored by directly 
measuring the fluorescence intensity of the tissue culture supernatant. Intracellular Gag was quantitated in parallel by 
direct fluorescence analysis of cell lysates, allowing us to normalize for Gag expression efficiency. The assay was 
validated by comparison with p24 capsid ELISA measurements, a standard method for quantifying HIV-1 particles. 
Optimization of conditions allowed the robust detection of particle amounts corresponding to 50 ng p24/ml in 
medium by fluorescence spectroscopy. Further adaptation to a multi-well format rendered the assay suitable for 
medium or high throughput screening of siRNA libraries to identify host cell factors involved in late stages of HIV 
replication, as well as for random screening approaches to search for potential inhibitors of HIV-1 assembly or release.
Conclusions: The fast and simple fluorescence based quantification of HIV particle release yielded reproducible results 
which were comparable to the well established ELISA measurements, while in addition allowing the parallel 
determination of intracellular Gag expression. The protocols described here can be used for screening of siRNA libraries 
or chemical compounds, respectively, for inhibition of HIV in a 96-well format.
Background
The acquired immunodeficiency syndrome (AIDS),
caused by infection with the human immunodeficiency
virus (HIV), is a major cause of disease and death world-
wide. In the absence of a protective vaccine, prevention of
infection and the treatment with antiretroviral drugs
remain the only options to prevent the spread of HIV and
combat the disease. Current therapy of HIV infection
(highly active antiretroviral therapy, HAART) involves
treatment with a combination of three or more drugs tar-
geting different steps in HIV replication [reviewed in [1]].
The benefits of HAART are limited by viral resistance
development and the transmission and spread of resistant
HIV variants. Therefore, additional treatment options
targeting alternative steps in the viral replication pathway
are needed. The late replication steps of virion assembly
and release are not targeted by any of the currently
approved antiretroviral drugs and thus present targets for
alternative inhibition strategies. The processes of HIV
particle assembly and release, as well as the morphologi-
cal maturation of particles into infectious virions, are
orchestrated by the main structural polyprotein Gag.
Compounds that do interfere with HIV infectivity in tis-
sue culture by interaction with the Gag polyprotein or its
capsid domain (CA), respectively, have been described.
The compounds bevirimat [[2]; reviewed in [3]] and
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CAP-1 [4,5], do not impair HIV immature particle
release, but affect the maturation into infectious particles
by binding to a proteolytic processing site in the Gag
polyprotein precursor or to the N-terminal domain of the
CA protein, respectively. Furthermore, a peptide (CAI),
which acts as a bona fide inhibitor of particle assembly
from purified HIV structural protein in vitro has been
reported [6,7]. A cell-permeable derivative of this peptide
has been shown in a proof of principle study to inhibit
HIV replication in tissue culture, albeit with IC50 values
in the low to mid μM range and a low selectivity index [8].
Small molecule chemical compounds which specifically
inhibit the steps of immature Gag assembly or particle
release have not yet been identified. Rational develop-
ment of such compounds is hindered by the fact that the
late stages in the viral life cycle are highly complex pro-
cesses involving the interaction of viral components with
intricate cellular machineries, which are currently only
partly understood. It is well established that components
of the cellular ESCRT machinery [9], which are recruited
by a so-called 'late domain' motif within Gag, are involved
in the budding of HIV particles from the host cell [for
review see [10]] and a number of additional cellular fac-
tors have been implicated to be involved in the late stages
of HIV replication [reviewed in [11,12]]. However, a com-
prehensive picture of cellular factors and pathways
involved in the transport, assembly and release of viral
components is currently lacking. Genome-wide siRNA
screening approaches have been carried out with the aim
of identifying host cell factors essential or inhibitory for
HIV replication [13-15]. So far, only two published stud-
ies include late stages of virus replication in their analysis,
and the results from the different studies showing sur-
prisingly little overlap [16-18]. The availability of simpli-
fied cell based assay procedures specifically monitoring
the steps of HIV assembly and particle release in tissue
culture would greatly facilitate both large-scale siRNA
analyses focussing in particular on the late stages of virus
replication, as well as the random screening of chemical
compound libraries in order to identify lead substances
which interfere with HIV particle formation. A well
established and widely used method for quantification of
HIV particle production is an enzyme linked immunosor-
bent assay (ELISA) detecting the viral capsid (CA) pro-
tein p24 in tissue culture supernatants. However, ELISA
measurements display a limited linear range and require
many handling steps and expensive reagents. In contrast,
measurement of fluorescence intensity is a direct, quanti-
tative readout which can easily be performed in a multi-
well format. Thus, we decided to establish a simplified
assay based on our previously described fluorescently
labelled HIV derivative carrying an eGFP moiety inserted
as a separate domain into the main viral structural poly-
protein Gag [[19,20]; Figure 1A]. Cells transfected with
the  egfp-carrying proviral construct release fluorescent
virus like particles in a late domain dependent manner
and we have previously used these labelled derivatives to
analyze the dynamics of HIV-1 particle formation [21].
Here, we describe a simple and direct assay for monitor-
ing HIV particle release through quantitation of fluores-
cent VLPs in tissue culture supernatant. Based on this
principle, we have established protocols suitable for the
screening of either siRNAs or chemical compounds for
their interference with HIV assembly and/or release in a
multi-well, medium to high throughput format.
Results and discussion
Setup of the assay procedure and optimization of assay 
conditions
The aim of this study was to develop a simple and direct
assay for HIV-1 release based on our previously charac-
terized fluorescently labelled HIV derivative [19,20],
which should allow the quantitation of particles in tissue
culture supernatants from virus producing cells by direct
measurement of fluorescence intensity. Towards this end,
we first optimized the detection conditions to increase
the sensitivity of the measurements in tissue culture
supernatants. Due to intrinsic fluorescence of tissue cul-
ture media components at the wavelengths used for
detection of fluorescent proteins, optimization of the
assay initially required the selection of the fluorophore
best suited for detection against medium background.
Fluorescence measurements of serial dilutions of bacteri-
ally expressed, purified enhanced green, cyan and yellow
fluorescent proteins (eGFP, eYFP, eCFP) as well as mono-
meric red fluorescent protein [22] in PBS and various tis-
sue culture media indicated that enhanced yellow
fluorescent protein eYFP was most suitable among these
fluorophors for detection against complete medium
background. EYFP concentrations above10 ng/ml were
detectable over medium background (Additional file 1,
Figure S1). Omission of phenol red or fetal calf serum
from the medium did not significantly alter the sensitivity
of detection.
Based on these findings, we constructed an HIV deriva-
tive carrying the eyfp gene within the gag open reading
frame, analogous to the previously described construct
pCHIVeGFP  [20]. The fluorescent protein was inserted
between the matrix (MA) and capsid (CA) domains of the
Gag polyprotein, upstream of the proteolytic processing
site between MA and CA (Figure 1A). Transfection of
cells with pCHIV and derivatives results in expression of
all viral proteins, except for Nef, under the control of the
CMV promoter and to formation and release of entry
competent virus like particles (VLPs). The genome
encoded by pCHIV is replication incompetent due to
deletion of the complete viral long terminal repeatHermle et al. BMC Biotechnology 2010, 10:32
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regions essential for reverse transcription and integra-
tion.
As shown in Figure 1B, cells transfected with
pCHIVeYFP  displayed the expected yellow fluorescence.
Furthermore, HeLaP4 cells which express the receptor
and co-receptors of HIV formed large syncytia upon
transfection with pCHIV derived constructs, indicative of
HIV Env protein expression. Cell lysates as well as parti-
cle preparations from the supernatant of transfected cells
were prepared and analyzed by immunoblot (Figure 1C).
Figure 1 Characterization of the fluorescently labelled virus derivatives. (A) Map showing the insertion of the eyfp gene within the gag open 
reading frame of pCHIV. Arrowheads indicate cleavage sites for HIV protease. (B) Fluorescence micrographs of HeLaP4 cells transfected with plasmids 
peYFP-C1, pCHIVeYFP or pCHIVeYFPlate(-), respectively, recorded at 40 h post transfection. Note that a shorter exposure time was used for cells transfect-
ed with peYFP-C1 to adjust for the higher cytoplasmatic fluorescence intensity. (C) Immunoblot analysis of cell lysates and VLPs purified from the su-
pernatant of transfected cells. At 36 h post transfection with peYFP-C1 (lanes 1 and 5), pCHIV (lanes 2 and 6), pCHIVeYFP (lanes 3 and 7) or pCHIVeYFPlate(-
) (lanes 4 and 8), respectively, cells were harvested and particles were prepared from the medium by ultracentrifugation through a sucrose cushion. 
Samples corresponding to equal cell numbers or equal amounts of supernatant were subjected to SDS-PAGE, transferred to a nitrocellulose mem-
brane and proteins were detected by enhanced chemiluminescence using the indicated antisera. Antiserum raised against GFP displayed cross-reac-
tivity against eYFP. (D) Relative release efficiencies of eYFP, HIVeYFP and HIVeYFPlate(-) particles. Relative eYFP fluorescence intensities of tissue culture 
supernatants and lysates of cells transfected with the indicated plasmids were determined at 44 h post transfection using a TECAN Safire multi-well 
reader. Values shown here were obtained by subtracting the background derived from untransfected cells and dividing extracellular by total (intrac-
ellular plus extracellular) fluorescence. Data shown represent mean values and standard deviations from three parallel transfections.
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Analogous to our results obtained with the related con-
struct pKHIVeGFP  [19], the Gag.eYFP fusion protein
expressed in the viral context was processed upon parti-
cle maturation by the viral protease to yield MA.eYFP,
and released pelletable particles containing the MA.eYFP
fusion protein in a late domain dependent manner (Fig-
ure 1C and data not shown). Accordingly, particles
should be detectable in the tissue culture supernatant by
measurement of eYFP fluorescence intensity.
Specific detection of released particles by fluorescence 
measurements
The exploitation of fluorescent MA for the quantitation
of specific particle release from cells transfected with
pCHIVeYFP  by fluorescence measurements required
appropriate controls. The fluorescence readout - analo-
gous to p24 determination by ELISA - does not necessar-
ily reflect the amount of complete particles released, but
rather quantitates the amount of the main particle com-
ponent Gag present in tissue culture supernatants. Con-
sequently, unspecific release of free Gag, p24 CA or
MA.eYFP from damaged or lysed cells could impair the
accuracy of results obtained by either ELISA or fluores-
cence based measurements. To control for unspecific
protein release due to cell damage, we used cells express-
ing unfused eYFP protein, which is not secreted from
intact cells, but will be detected in the medium when the
sample contains cell debris or cytoplasmic content from
lysed cells. Secondly, a positive control for the successful
inhibition of release was established. For this purpose, we
generated a release deficient variant of the fluorescently
labelled HIV derivative by replacing the 'late domain'
motif PTAP within the p6 domain of Gag.eYFP with the
amino acid sequence LIRL. The late domain is known to
mediate interaction with the host cell ESCRT machinery
[see [10] for review] and its mutation to LIRL has been
previously shown to affect HIV release efficiency [23]. An
inhibitory compound which directly blocks viral late
domain - ESCRT interaction or an siRNA which down-
modulates expression of a late domain interacting host
factor can be expected to yield a comparable decrease in
release efficiency as the mutation of the late domain,
while compounds or siRNAs targeting the Gag assembly
process may theoretically accomplish even stronger
reduction.
Expression of the Gag.eYFP.late(-) fusion protein and
the release deficiency of this construct was confirmed by
immunoblot analysis of cell lysate and pelleted tissue cul-
ture supernatant (Figure 1C). While comparable amounts
of Gag.eYFP and Gag.eYFP.late(-) were detected in cell
lysates (compare lanes 3 and 4), the amount of Gag
derived products in pelleted particles was significantly
decreased in the case of the late-variant (compare lanes 7
and 8). Free eYFP was expressed in transfected cells (lane
1), but not detected in pelleted supernatant (lane 5). We
then determined the relative release efficiency of
Gag.eYFP.late(-) by fluorescence measurements.
Figure 1D shows the result of a comparison of release
efficiencies between 293T cells transfected with plasmids
pEYFP-C1, pCHIV and pCHIVeYFPlate(-). At 48 h post
transfection tissue culture supernatants were harvested
and cells were lysed by detergent treatment as described
in methods. Supernatants from particle producing cells
displayed typical spectroscopic characteristics of eYFP
with excitation and emission maxima at 512 nm and 527
nm (Additional file 2, Figure S2). Relative release efficien-
cies were calculated by dividing fluorescence intensities
measured in tissue culture supernatants by the corre-
sponding total fluorescence intensities measured in
supernatants and cell lysates. Cells transfected with plas-
mid peFYP-C1 displayed high intracellular fluorescence
but the relative amount of eYFP released into the super-
natant was low in comparison to cells transfected with
pCHIVeYFP. Cells expressing the late domain defective
variant of the labelled virus reproducibly showed an
approximately five-fold reduction of relative release effi-
ciency as compared to cells expressing the wild-type vari-
ant.
Sensitivity of measurements
O u r  p r e v i o u s  c h a r a c t e r i z a t i o n  o f  e G F P  l a b e l l e d  H I V
derivatives had revealed that - while bulk release effi-
ciency of labelled virus was comparable to wild-type -
cells expressing the labelled HIV derivative displayed
electron dense aggregates at the plasma membrane, sug-
gesting altered release kinetics; furthermore released par-
ticles displayed reduced infectivity. Full wild-type particle
infectivity and budding site morphology was restored by
co-transfection of an equimolar amount of wild-type HIV
proviral plasmid, leading to the formation of mixed parti-
cles carrying 50% of labelled Gag [19]; assuming an aver-
age number of approximately 2400 molecules of Gag per
particle [24], particles contain thus approximately 1200
molecules of fluorescent protein. For this reason,
equimolar mixtures of eYFP labelled proviral derivatives
with the corresponding non-labelled provirus were used
in all further experiments.
In order to determine the sensitivity of fluorescence
based particle quantification, VLPs were prepared from
the tissue culture supernatant of cells co-transfected with
an equimolar mixture of pCHIV and pCHIVeYFP by ultra-
centrifugation through a sucrose cushion. The amount of
CA p24 present in the particle preparation was deter-
mined by ELISA, which represents a currently used stan-
dard method for HIV particle quantification. Since both
eYFP and p24 CA are expressed from pCHIVeYFP as parts
of the Gag polyprotein, they are translated and packaged
into VLPs at equimolar amounts; in the case of the mixedHermle et al. BMC Biotechnology 2010, 10:32
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particles used here, one molecule of eYFP will thus corre-
spond to two molecules of CA. Serial dilutions of fluores-
cent particles in complete medium were set up and their
relative eYFP fluorescence intensity was determined (Fig-
ure 2). The lowest particle concentration detectable
above background by fluorescence measurements in
complete medium corresponded to approximately 15-30
ng CA/ml (equivalent to ~8-15 ng eYFP/ml), which was
in good agreement with the results from measurements
using purified fluorescent proteins. Omission of FCS or
phenol red from the medium or replacement of the
medium by PBS only resulted in a minor increase in sen-
sitivity (data not shown). From these and similar data sets
we concluded that robust fluorescence intensity quantita-
tion can be performed for particle concentrations corre-
sponding to 50 ng p24/ml or higher. This sensitivity is
significantly lower than that of advanced ELISA based
detection systems [25]. However, this does not affect the
usefulness of the system for the intended applications,
since the amounts of particles released under optimized
assay conditions were in a range easily detectable by fluo-
rescence measurements (see below).
Assay validation and time course of particle release
We then analysed the time course of fluorescence release
from cells transfected with equimolar mixtures of either
wild-type or late domain defective variants of pCHIV/
pCHIVeYFP, respectively. Samples of tissue culture super-
natant were removed at consecutive time points between
24 and 48 h post transfection and subjected to fluores-
cence measurements. Cells transfected with peYFP-C1
were used as a negative control. In order to investigate
whether budding of HIV from the membrane could pro-
mote the release of free eYFP from cells, we included cells
transfected with a mixture of pCHIV and peFYP-C1 as an
additional control. At 48 h post transfection, cells were
lysed by detergent treatment and the fluorescence inten-
sity of the lysate determined in order to normalize for
transfection efficiency and Gag or eYFP expression in the
different samples. As shown in Figure 3A, fluorescence in
the supernatant above background was detectable at 24 h
post transfection with pCHIV/pCHIVeYFP (filled circles)
and increased over the following hours. Again, release
from the late(-) variant (open circles) was found to be
diminished. While fluorescence in the supernatant of
peYFP-C1 transfected cells (open triangles) remained at
Figure 2 Titration of eYFP labelled VLPs. Mixed particles were purified from the tissue culture supernatant of 293T cells transfected with an equimo-
lar mixture of pCHIV and pCHIVeYFP by centrifugation through a sucrose cushion and their concentration determined by p24 ELISA. The relative eYFP 
fluorescence intensity of serial dilutions in DMEM/10% FCS was determined using a TECAN Saphire multi-well reader. Background fluorescence from 
the medium was subtracted and fluorescence intensities of the samples were plotted as a function of p24 CA concentration. The plot shows mean 
values and standard deviation from triplicate dilutions; the line represents a linear regression. The inset shows an expansion of the lower part of the 
same data set. The line represents a linear regression to the data points shown.
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background levels, release of low levels of free eYFP was
promoted in the presence of HIV expression (filled trian-
gles). This might be explained by unspecific packaging of
cytosolic eYFP into budding virus particles, since we
observed that in this case release was also influenced by
the presence of a functional HIV late domain (data not
shown).
Results obtained from fluorescence measurements
were validated by determination of p24 CA in the same
samples by ELISA. Again, we calculated the amount of
p24 in the supernatant relative to the amount measured
in cell lysates at 48 h. Results are shown in Figure 3B.
Similar concentrations of p24 were detected in superna-
tants from cells transfected with pCHIV/pCHIVeYFP
(filled circles) and with pCHIV/peYFP-C1 (filled trian-
gles), demonstrating that insertion of eYFP within Gag
did not affect release efficiency; p24 concentrations mea-
sured corresponded to ~70 ng/ml at 24 h post transfec-
tion and ~0.5 μg/ml at the end of the experiment,
respectively. Evaluation by ELISA yielded similar results
for pCHIV/pCHIVeYFP (filled circles) and pCHIVlate(-)/
pCHIVeYFPlate(-) (open circles) as the fluorescence based
assay (compare Figure 3A and Figure 3B), confirming the
validity of the fluorescence assay method. A slightly
larger deviation between parallel samples was observed
in the ELISA experiment, presumably because this proce-
dure involved more handling steps. The observation that
the relative ratio of intra- to extracellular fluorescence
differs somewhat between the two types of measurement
is explained by the fact that unprocessed Gag (which rep-
resents the predominant form in cell lysates) is recog-
nized less well than processed CA (the predominant form
in particles), by immunoprecipitation [26] or ELISA.
Even prior heat and detergent treatment of samples,
which has been reported to make unprocessed Gag acces-
sible to ELISA detection [27], did not confer full reactivity
of the precursor form in our hands. Thus, data derived
from the ELISA measurements are less suitable for reli-
able normalization of CA levels relative to intracellular
Gag expression levels. In contrast, in vitro cleavage of
immature fluorescent particles using purified PR did not
result in a change in fluorescence intensity, demonstrat-
ing that the fluorescence based quantitation of Gag was
independent of its processing status (data not shown). We
concluded that the assay described here is suitable to
monitor HIV-1 particle release and can be used to test
inhibition of HIV-1 particle formation in tissue culture.
In order to define conditions yielding efficient late
domain dependent release accompanied by low levels of
unspecific release we compared the ratio between release
of the wild-type and late(-) virus variants at the different
time points. The ratio of late(-) particles released com-
pared to wild-type particles increased at later time points,
presumably due to unspecific Gag release from damaged
or dead cells upon prolonged protein over-expression
(Figure 3C and data not shown), indicating that harvest
times of 33-36 h post transfection were optimal under the
conditions used.
Adaptation of the assay to medium throughput formats
Further adaptation of the assay to a semi-automated
multi-well format was performed to render the assay suit-
able for random screening. Two different protocols were
established suitable for screening of chemical compound
Figure 3 Time course of labelled VLP release cells determined by fluorescence measurement or ELISA, respectively. 293T cells were transfect-
ed with mixtures of pCHIV/pCHIVeYFP (filled circles) or pCHIVlate(-)/pCHIVeYFPlate(-) (open circles), respectively. Cells transfected with peYFP-C1/empty 
vector (open triangles) or peYFP/pCHIV (filled triangles) served as controls. At the indicated time points after transfection, tissue culture supernatants 
were sampled and analyzed in parallel by fluorescence measurements (A) or ELISA (B), respectively, as described in methods. To control for transfec-
tion efficiency, cell lysates prepared at the end of the experiment were subjected to the same analyses. Normalized release efficiency was determined 
by subtracting the background derived from untransfected cells and dividing extracellular fluorescence or p24 CA versus intracellular fluorescence or 
p24 CA determined at 48 h post transfection, respectively. Data represent mean values and standard deviations from triplicate transfections. (C) In-
crease of unspecific release upon prolonged incubation of cells. Normalized release values for HIVlate(-)/HIVeYFPlate(-) determined in the experiment 
shown in Figure 3A at the indicated times post transfection were divided by the respective values obtained for HIV/HIVeYFP.
20 30 40 50
0.0
0.5
1.0
1.5
2.0
2.5
time post transfection [h]
R
F
I
s
u
p
 
/
 
t
r
a
n
s
f
e
c
t
i
o
n
 
e
f
f
i
c
i
e
n
c
y ABC
1 2 3 4 5
0.00
0.05
0.10
0.15
r
e
l
a
t
i
v
e
 
r
e
l
e
a
s
e
 
r
a
t
i
o
 
[
l
a
t
e
(
-
)
/
w
t
]
24      28     32     36     48
time post transfection [h] time post transfection [h]
p
2
4
s
u
p
 
/
 
t
r
a
n
s
f
e
c
t
i
o
n
 
e
f
f
i
c
i
e
n
c
y
20 30 40 50
0.0
0.5
1.0
1.5
2.0
2.5Hermle et al. BMC Biotechnology 2010, 10:32
http://www.biomedcentral.com/1472-6750/10/32
Page 7 of 12
libraries or for siRNA screening approaches, respectively.
For the purpose of compound screening we established a
protocol for the bulk transfection of 293T cells. Briefly,
293T cells were harvested and transfected in suspension
using equimolar mixtures of pCHIV/pCHIVeYFP, pCHIV-
late(-)/pCHIVeYFPlate(-), or plasmid peYFP-C1 alone,
respectively. Cell suspensions were then distributed into
wells of a 96-well plate or 384-well plate, respectively,
using an automated reagent dispenser and plates were
incubated at 37°C. The addition of chemical compounds
dissolved in DMSO was mimicked by the addition of a
final concentration of 0.5% DMSO to the medium at 14 h
post transfection. At 36 h post transfection, plates were
briefly spun to pellet potential cell debris. Aliquots of tis-
sue culture supernatants were transferred to fresh plates
using an automated liquid handler, the remaining super-
natant was removed from the cell layer and cells were
lysed on the plate as described in methods. Relative fluo-
rescence intensities of supernatants and cell lysates were
determined using a TECAN Safire multi-well reader.
Supernatants and lysates from untransfected cells were
used to determine background fluorescence. As shown in
Figure 4 and Additional file 3, Figure S3, this procedure
yielded robust results in 96-well plates. A limited data set
of 60 positive (cells transfected with pCHIV/pCHIVeYFP,
0.5% DMSO) and 36 negative (untransfected cells) con-
trol wells from a pilot screen including 6 replicate plates
was used to estimate statistical effect size, yielding a Z
factor [28] of 0.71 (Additional file 3, Figure S3). Mean flu-
orescence intensities in the supernatant of 176 wells from
88 plates (Figure 4A, grey bars) showed low plate-to-plate
variability. The amount of eYFP labelled protein released
into the supernatant by the late domain defective variant
was reduced to 16% of the wild-type control. Very similar
results were obtained when fluorescence intensities of the
supernatant normalized to the total fluorescence mea-
sured in the supernatant and cell lysate were compared
(Figure 4A, black bars). Thus, normalization for intracel-
lular protein expression was not necessary to improve the
accuracy of measurements in a standardized 96-well
setup. In the context of a random screening assay, how-
ever, the parallel determination of intracellular eYFP
intensity in a screening assay can serve to identify com-
pounds which do not specifically interfere with HIV par-
ticle formation but rather exert a general effect on protein
expression. Comparison of relative release efficiencies
determined for labelled wild-type particles across rows 2-
11 of 96-well plates in the absence of inhibitory com-
pounds did not reveal any systematic aberration across
the plate (Figure 4B). We conclude that the assay allows
for medium throughput screening of potential inhibitors
of HIV-1 assembly or release.
Transfer of the protocol to a 384-well format yielded
less robust results (Figure 4C). Due to difficulties in
reproducible preparation and measurement of cell lysates
in the small well format, normalization of supernatant
fluorescence to total fluorescence led to larger variability
between wells (data not shown). While the assay in its
present form could be used to determine relative
amounts of Gag released into the supernatant using a
384-well format, further optimization would be required
for a reliable parallel quantification of intracellular Gag.
Finally, a modified protocol was established to be used
in screening of siRNA libraries for factors involved in
HIV release. For this, 293T cells were distributed onto
96-well plates which had been pre-coated with an siRNA
containing transfection mix using a previously described
reverse transfection protocol [29,30]. Dried pre-coated
plates could be either used directly for knockdown exper-
iments or be stored for up to 15 months without any loss
of efficacy, thus ensuring improved reproducibility and
comparability between different plates of the same batch
as compared to liquid transfection of siRNA. 293T cells
were seeded onto these plates and incubated in order to
achieve target gene knockdown, followed by transfection
with pCHIV/pCHIVeYFP and further incubation. In order
to validate this approach we performed siRNA mediated
knockdown of the cellular ESCRT protein Tsg101, which
has been previously shown to impair HIV release [31]. At
the conditions used, prolonged knock-down of Tsg101
resulted in reduced cell viability and cell death; to avoid
this, we chose a relatively short incubation period of 18 h
for the initial transfection with siRNA, followed by trans-
fection with pCHIV/pCHIVeYFP. Incubation was then
continued for 36 h before read out of fluorescence inten-
sities in supernatant and cell lysates was carried out. As
shown in Figure 5A, siRNA mediated knock-down of
Tsg101 resulted in an approximately 4-5 fold reduction in
release efficiency under these conditions, which was only
slightly less pronounced than the reduction observed
using the late(-) virus variant.
We have performed a pilot screen, in which we tested
an siRNA library (silencer siRNAs, Ambion, Applied Bio-
systems) targeting approximately 740 human kinases
with one individual siRNA per well and three distinct siR-
NAs per target gene. Since individual siRNAs from this
library have not been tested for their silencing properties
and time course of gene silencing, we chose longer incu-
bation times of 30 h after the initial transfection with
siRNA and 42 h after the second transfection. The results
of this screen and the validation of primary hits will be
described elsewhere. Exemplary for the reproducibility of
results obtained using the established protocol, Figure 5B
shows the correlation of relative release values (RFIsup/
RFItotal) obtained for two replicate sets of 480 wells from
the siRNA screen. The values obtained for RFIsup/RFItotal
were slightly higher than those observed for the com-Hermle et al. BMC Biotechnology 2010, 10:32
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Figure 4 Adaptation of the assay to a multi-well format. (A) Reproducibility of controls. 293T cells transfected with an equimolar mixture of pCHIV 
and pCHIVeYFP (wild-type) or their late domain defective variants (late(-)) were seeded into 96-well plate. Fluorescence intensities of tissue culture su-
pernatants (grey bars) or release efficiencies (supernatant fluorescence intensities divided by total fluorescence intensity (supernatant and cell lysate; 
black bars) were determined as described in methods. Bars represent mean value and standard deviation of 176 wells from 88 plates. (B) Variability 
across a 96-well plate. 293T cells transfected with an equimolar mixture of pCHIV and pCHIVeYFP were seeded into 96-well plate. 0.5% of DMSO was 
added to the medium at 14 h post transfection to mimic the addition of compounds dissolved in DMSO. Supernatants and cell lysates were harvested 
at 36 h post transfection and relative release efficiencies were determined by dividing extracellular by total fluorescence and normalized by dividing 
through the median of release efficiencies from all wells of the respective plate. Mean values and standard deviations from three 96-well plates are 
shown. (C) Variability across a 384-well plate. 293T cells transfected with a mixture of pCHIV/pCHIVeYFP (black bars) or their late domain defective vari-
ants (grey bars), respectively, were seeded into a 384-well plate. Relative fluorescence intensities of the supernatants were measured at 34 h post trans-
fection. Mean values and standard deviations from 24 wells each are shown.
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pound screen setup due to the modified assay procedure.
Pearson's correlation coefficients between replicates of
identical siRNA sets were generally found to be in the
range of 0.7 - 0.8, indicating that the setup described here
allowed us to obtain reproducible results in a 96 well for-
mat.
Conclusion
We conclude that direct measurement of fluorescence
intensities after transfection of cells with a labelled HIV
derivative represents a reliable method for monitoring
HIV particle release, which is suitable for use in random
screening approaches to search for chemical inhibitors or
siRNAs specifically interfering with HIV assembly or
release.
Methods
Plasmids
Plasmid pCHIVeYFP was constructed by inserting a PCR
fragment comprising the complete eYFP coding sequence
from peYFP-C1 (Invitrogen) into an engineered ClaI-site
between the codons for amino acids 128 and 129 of MA.
The cloning strategy for this construct, as well as for its
late domain defective variant was analogous the cloning
strategy previously described for eGFP labelled virus
variants [19,20]. Plasmids for the expression of recombi-
nant His-tagged eGFP, eYFP and eCFP were generated by
cloning PCR fragments comprising the respective coding
sequences into the NdeI and BamHI sites of pET16b
(Novagen). Plasmid pmRSETmRFP1 was a kind gift of R.
Tsien.
Tissue culture and virus preparation
293T and HeLaP4 cells were cultured at 37°C, 5% CO2 in
Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% fetal calf serum (FCS), penicillin, strep-
tomycin, 4 mM glutamine and 10 mM Hepes. For viral
particle preparation, 293T cells were transfected with
pCHIVeYFP or with an equimolar mixture of pCHIVeYFP
and pCHIV as indicated by standard calcium phosphate
precipitation. Tissue culture supernatants were harvested
at 40-44 h post transfection, filtered through 0.45 μm fil-
ters and particles were concentrated by ultracentrifuga-
tion through a 20% (w/w) sucrose cushion. Virus
preparations and cell lysates were separated by SDS-
PAGE (17.5%, acrylamide:bisacrylamide 200:1) trans-
ferred to nitrocellulose and analyzed by ECL immunoblot
(Pierce) using polyclonal rabbit antisera raised against
purified recombinant His-tagged HIV MA and GFP,
respectively. The antiserum raised against GFP displays
cross-reactivity with the GFP derivative eYFP. For quanti-
tation of virus by ELISA, tissue culture supernatants or
particle preparations, respectively, were diluted with
SDS-Sample buffer (final concentration 0.1% SDS) and
incubated for 5 min at 95°C to enhance antibody recogni-
tion of unprocessed Gag. Samples were subsequently
Figure 5 Adaptation of the assay for an siRNA screening approach. (A) Reduction of relative release efficiency by knock-down of Tsg101. 96-well 
plates were coated with non-silencing control siRNA or siRNA targeting Tsg101, respectively, as described in methods. 293T cells were seeded onto 
those plates for reverse transfection and incubated for 18 h at 37°C. Subsequently, cells were transfected with a mixture of pCHIV/pCHIVeYFP or their 
late domain defective variants, respectively. Supernatants and cell lysates were harvested at 36 hours after this second transfection and relative fluo-
rescence intensities were determined. Relative release efficiencies (RFIsup/RFItotal) were normalized to the mean of the non-silencing control. Mean val-
ues and standard deviations from triplicate transfections are shown; black bars and gray bars, respectively, represent results from two independent 
experiments. (B) Reproducibility of results obtained in a pilot siRNA screen. The graph shows the correlation between normalized eYFP intensities (eY-
FP intensity of supernatant divided by total eYFP intensity; RFIsup/RFItotal) of two replicates of an RNAi screen investigating host cell functions in HIV-1 
assembly and release, comprising a total of 480 wells in 96-well plates. Each dot represents an individual siRNA mediated gene knockdown. The Pear-
son's correlation coefficient was calculated using GraphPad Prism.
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diluted in PBS/0.1% Tween 20 before incubation with
capture antibody. The concentration of CA p24 in the
samples was determined by ELISA as previously
described [32].
Fluorescence measurements of particle preparations
were carried out at room temperature in phosphate buff-
ered saline or DMEM/10% FCS as indicated using a
TECAN Safire multi-well reader set to excitation and
emission wavelengths of 512 nm and 528 nm, or an
Aminco-Bowman SLM-2 spectrophotometer for cuvette
based measurements, respectively.
Release assay
293T cells were transfected with pCHIVeYFP, pCHIVeYF-
Plate(-) or peYFP-C1, respectively, using calcium phos-
phate or FuGene 6 (Roche) according to standard
procedures. At the indicated time points, samples of tis-
sue culture supernatant were removed, briefly centri-
fuged to remove cell debris (5 min, 3000 g) and subjected
to fluorescence measurement. At the end of the indicated
incubation period, the remaining medium was removed,
cells were briefly washed with phosphate buffered saline
(PBS) and incubated in lysis buffer (PBS/0.5% Igepal) at a
volume corresponding to the volume of the tissue culture
supernatant. Cells were incubated for 10 min at room
temperature and cell debris was removed by brief centrif-
ugation (2 min, 1500 g). Fluorescence measurements of
supernatants and cell lysates were carried out using an
SLM Aminco 2 spectrofluorometer.
For the semi-automated multi-well screening approach,
a protocol for batch transfection of cells in suspension
was established. 293T cells grown on 10 cm dishes were
harvested by trypsinization and adjusted to 3 × 105cells/
ml in DMEM without FCS. Per 96-well plate, 960 μl of
DMEM without FCS was mixed with 38.4 μl FuGene6
(Roche). Following 5 min incubation at room tempera-
ture 19.2 μg of total plasmid DNA were added and the
mixture incubated for further 15 min at room tempera-
ture. Subsequently, 9.6 ml of the cell suspension were
added and 110 μl of the transfection mixture was seeded
per well onto 96-well plates (Corning COSTAR #3603) or
25 μl per well onto 384-well plates (BD FALCON 353962,
BD Biosciences) using an automated reagent dispenser
(MultiDrop® Combi). Plates were incubated at 37°C. At 36
h post transfection, plates were centrifuged (1500 rpm, 8
min) and 87.5 μl of the supernatant was transferred to
new 96-well plates (Corning COSTAR #3916) or 20 μl to
384-well plates (BD FALCON 353962) using the compact
automated liquid handler Hydra DT (Matrix, Thermo
Fisher Scientific). The residual supernatant was removed
and 100 μl (96-well plates) or 25 μl (384-well plates) 0.1%
Igepal CA630 (Sigma-Aldrich) in PBS were added to each
well, followed by one freeze-thaw cycle to promote cell
lysis. Fluorescence intensities of supernatants and cell
lysates were determined using a multi-well fluorescence
reader (Tecan SAFIRE).
Screening of an siRNA library required several modifi-
cations of this procedure. The plates used for seeding the
cells were pre-coated with an siRNA transfection mixture
using a previously described reverse transfection proto-
col [29,30] and liquid handling platform [33]. Briefly, a
mixture of the respective siRNA, the transfection reagent
Lipofectamine 2000 (Invitrogen), fibronectin (Sigma-
Aldrich), sucrose and gelatine were transferred automati-
cally to 96-well plates (Corning COSTAR #3603).
Silencer®  Select Negative Control #1 siRNA (Ambion
Applied Biosystems) was used as a non-silencing control.
For the knock-down of Tsg101 we used siRNA with the
sequence 5'CCUCCAGUCUUCUCUCGUC3' selected
according to Garrus et al. [31]. 293T cells were seeded on
top of the dried transfection mixture (7500 cells/well in
100 μL D-MEM 10% FCS) using the reagent dispenser
MultiDrop®  Combi. Following a 30 hour incubation
period at 37°C (18 h for Tsg101, respectively) for target
gene knockdown, medium was removed and cells were
transfected with an equimolar mixture of plasmids
pCHIV and pCHIVeYFP using FuGene6 (Roche) according
to the manufacturer's instructions. Per well, 100 ng plas-
mid DNA in 100 μl medium were added. After an addi-
tional 42 h at 37°C (36 h for Tsg101) tissue culture
supernatants and cell lysates were harvested and their
RFI values were quantitated as described above.
Additional material
Additional file 1 Figure S1: Detection of purified fluorescently 
labelled proteins against medium background. Fluorescent proteins 
eGFP (open circles), eYFP (filled circles), eCFP (open triangles) and mRFP1 
(open squares), respectively, were expressed as recombinant His-tagged 
proteins in Escherichia coli. Proteins were purified by Ni-chelate affinity chro-
matography using 1 ml HisTrap columns (GE Healthcare) according to the 
manufacturer's instructions and dialyzed against PBS. Protein Party was ver-
ified by SDS-PAGE and concentrations were calculated from OD280 values 
determined for GuHCl denatured proteins using extinction coefficients of 
21890 (eGFP), 23380 (eYFP), 25900 (eCFP) and 32890 (mRFP), respectively. 
Serial dilutions were set up in DMEM, 10% FCS, and fluorescence intensity 
was determined at the appropriate wavelength settings (488/508 nm, 512/
528 nm, 433/475 nm and 584/607 nm, respectively) using a TECAN Safire 
multi-well reader. Background values obtained for medium alone were sub-
tracted. Mean values and standard deviations of triplicate dilutions are 
shown; lines represent linear regressions. Figure S1 B shows an expansion of 
the lower part of the graph shown in Figure S1 A.
Additional file 2 Figure S2: Fluorescence spectra of tissue culture 
supernatants. Fluorescence emission spectra of tissue culture superna-
tants harvested at 36 h post transfection from 293T cells transfected with 
pCHIVeYFP (black solid line), pCHIVeYFPlate(-) (grey solid line), peYFP-C1 (black 
dotted line), or from untransfected cells (grey dotted line), respectively, 
were recorded using an SLM Aminco Spectrofluorometer (excitation wave-
length: 512 nm).Hermle et al. BMC Biotechnology 2010, 10:32
http://www.biomedcentral.com/1472-6750/10/32
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Abbreviations
HIV: human immunodeficiency virus; ESCRT: endosomal complex required for
transport; eYFP: enhanced yellow fluorescent protein; MA: matrix protein; CA:
capsid protein; ELISA: enzyme linked immunosorbent assay; RFI: relative fluo-
rescence intensity; PBS: phosphate buffered saline; siRNA: short interfering
RNA.
Authors' contributions
JH adapted the protocol to a semi-automated format, established the protocol
for the siRNA screening approach and participated in the design of experi-
ments. MA performed the experiments for the initial characterization and vali-
dation of the assay procedure. AMH contributed to adaptation and validation
of the semi-automated procedure. BM conceived and coordinated the study,
participated in its design, performed initial experiments and drafted the manu-
script. All authors have read and approved the final manuscript.
Acknowledgements
We sincerely thank Hans-Georg Kräusslich for continuous support and critical 
reading of the manuscript. The help of Holger Erfle and his group for help with 
the preparations for the siRNA experiments is gratefully acknowledged. We 
thank Roger Tsien for the gift of plasmid pmRSET.mRFP1. This work is part of 
the activities of the HIV-ACE research network (HEALTH-F3-2008-201095), 
which is supported by a grant of the European Commission within the Priority 
1 "Health" work programme of the 7th Framework Programme of the EU. The 
work has also been funded in part by a grant from the Deutsche Forschungs-
gemeinschaft (MU885/4-2) and by the BMBF funded project Viroquant 
(0313923).
Author Details
Department of Infectious Diseases, Virology, University Hospital Heidelberg, Im 
Neuenheimer Feld 324, D-69120 Heidelberg, Germany
References
1. Hofmann WP, Soriano V, Zeuzem S: Antiviral combination therapy for 
treatment of chronic hepatitis B, hepatitis C, and human 
immunodeficiency virus infection.  Handbook of experimental 
pharmacology 2009:321-346.
2. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo 
A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT: 
PA-457: a potent HIV inhibitor that disrupts core condensation by 
targeting a late step in Gag processing.  Proceedings of the National 
Academy of Sciences of the United States of Americ 2003, 
100(23):13555-13560.
3. Salzwedel K, Martin DE, Sakalian M: Maturation inhibitors: a new 
therapeutic class targets the virus structure.  AIDS reviews 2007, 
9(3):162-172.
4. Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, Barklis E, Sun Y, Huang M, 
Summers MF: Antiviral inhibition of the HIV-1 capsid protein.  Journal of 
molecular biology 2003, 327(5):1013-1020.
5. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, Robinson H, Sundquist WI, 
Summers MF, Hill CP: Structure of the antiviral assembly inhibitor CAP-1 
complex with the HIV-1 CA protein.  Journal of molecular biology 2007, 
373(2):355-366.
6. Sticht J, Humbert M, Findlow S, Bodem J, Müller B, Dietrich U, Werner J, 
Kräusslich HG: A peptide inhibitor of HIV-1 assembly in vitro.  Nature 
structural & molecular biology 2005, 12(8):671-677.
7. Ternois F, Sticht J, Duquerroy S, Kräusslich HG, Rey FA: The HIV-1 capsid 
protein C-terminal domain in complex with a virus assembly inhibitor.  
Nature structural & molecular biology 2005, 12(8):678-682.
8. Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, 
Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK: A cell-penetrating 
helical peptide as a potential HIV-1 inhibitor.  Journal of molecular 
biology 2008, 378(3):565-580.
9. Wollert T, Yang D, Ren X, Lee HH, Im YJ, Hurley JH: The ESCRT machinery 
at a glance.  Journal of Cell Science 2009, 122(Pt 13):2163-6.
10. Morita E, Sundquist WI: Retrovirus budding.  Annual review of cell and 
developmental biology 2004, 20:395-425.
11. Klein KC, Reed JC, Lingappa JR: Intracellular destinies: degradation, 
targeting, assembly, and endocytosis of HIV Gag.  AIDS Reviews 2007, 
9(3):150-61.
12. Bieniasz PD: The cell biology of HIV-1 virion genesis.  Cell host & microbe 
2009, 5(6):550-8.
13. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, 
Lieberman J, Elledge SJ: Identification of host proteins required for HIV 
infection through a functional genomic screen.  Science 2008, 
319(5865):921-926.
14. König R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, 
Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS, Weitzman 
MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, Miraglia LJ, Bushman 
FD, Young JA, Chanda SK: Global analysis of host-pathogen interactions 
that regulate early-stage HIV-1 replication.  Cell 2008, 135(1):49-60.
15. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, 
Strulovici B, Hazuda DJ, Espeseth AS: Genome-scale RNAi screen for host 
factors required for HIV replication.  Cell host & microbe 2008, 4(5):.
16. Goff SP: Knockdown screens to knockout HIV-1.  Cell 2008, 
135(3):417-420.
17. Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, Diamond TL, 
Zhou H, Hazuda DJ, Espeseth AS, Konig R, Bandyopadhyay S, Ideker T, Goff 
SP, Krogan NJ, Frankel AD, Young JA, Chanda SK: Host cell factors in HIV 
replication: meta-analysis of genome-wide studies.  PLoS pathogens 
2009, 5(5):e1000437.
18. Prudencio M, Lehmann MJ: Illuminating the host - how RNAi screens 
shed light on host-pathogen interactions.  Biotechnology journal 2009, 
4(6):826-837.
19. Müller B, Daecke J, Fackler OT, Dittmar MT, Zentgraf H, Kräusslich HG: 
Construction and characterization of a fluorescently labeled infectious 
human immunodeficiency virus type 1 derivative.  Journal of virology 
2004, 78(19):10803-10813.
20. Lampe M, Briggs JA, Endress T, Glass B, Riegelsberger S, Kräusslich HG, 
Lamb DC, Bräuchle C, Müller B: Double-labelled HIV-1 particles for study 
of virus-cell interaction.  Virology 2007, 360(1):92-104.
21. Ivanchenko S, Godinez WJ, Lampe M, Kräusslich HG, Eils R, Rohr K, 
Bräuchle C, Müller B, Lamb DC: Dynamics of HIV-1 Assembly and 
Release.  PLoS Pathogens 2009, 5(11):e1000652.
22. Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA, 
Tsien RY: A monomeric red fluorescent protein.  Proceedings of the 
National Academy of Sciences of the United States of America 2002, 
99(12):7877-7882.
23. Huang M, Orenstein JM, Martin MA, Freed EO: p6Gag is required for 
particle production from full-length human immunodeficiency virus 
type 1 molecular clones expressing protease.  Journal of virology 1995, 
69(11):6810-6818.
24. Carlson LA, Briggs JA, Glass B, Riches JD, Simon MN, Johnson MC, Müller B, 
Grunewald K, Kräusslich HG: Three-dimensional analysis of budding 
sites and released virus suggests a revised model for HIV-1 
morphogenesis.  Cell host & microbe 2008, 4(6):592-599.
25. Ly TD, Ebel A, Faucher V, Fihman V, Laperche S: Could the new HIV 
combined p24 antigen and antibody assays replace p24 antigen 
specific assays?  Journal of virological methods 2007, 143(1):86-94.
26. Ono A, Waheed AA, Joshi A, Freed EO: Association of human 
immunodeficiency virus type 1 gag with membrane does not require 
highly basic sequences in the nucleocapsid: use of a novel Gag 
multimerization assay.  Journal of virology 2005, 79(22):14131-14140.
27. Wyma DJ, Jiang J, Shi J, Zhou J, Lineberger JE, Miller MD, Aiken C: 
Coupling of human immunodeficiency virus type 1 fusion to virion 
maturation: a novel role of the gp41 cytoplasmic tail.  Jornal of virology 
2004, 78(7):3429-35.
Additional file 3 Figure S3: Determination of Z factor from control 
wells of a pilot screen. Fluorescence intensities of supernatants from 60 
positive control wells (transfected with pCHIV/pCHIVeYFP, 0.5% DMSO) and 
36 negative control wells (untransfected cells) from 6 replicate 96-well 
plates were determined. The graph shows mean values and standard devia-
tions (SD) derived from these data. The Z factor [28] was calculated from 
these data using the formula Z = 1 - (3 × (SDpos + SDneg))/(meanpos - mean-
neg), yielding a value of 0.71.
Received: 10 November 2009 Accepted: 20 April 2010 
Published: 20 April 2010
This article is available from: http://www.biomedcentral.com/1472-6750/10/32 © 2010 Hermle et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Biotechnology 2010, 10:32Hermle et al. BMC Biotechnology 2010, 10:32
http://www.biomedcentral.com/1472-6750/10/32
Page 12 of 12
28. Zhang JH, Chung TD, Oldenburg KR: A Simple Statistical Parameter for 
Use in Evaluation and Validation of High Throughput Screening 
Assays.  Journal of Biomolecular Screening 1999, 4(2):67-73.
29. Erfle H, Neumann B, Liebel U, Rogers P, Held M, Walter T, Ellenberg J, 
Pepperkok R: Reverse transfection on cell arrays for high content 
screening microscopy.  Nature protocols 2007, 2(2):392-399.
30. Erfle H, Neumann B, Rogers P, Bulkescher J, Ellenberg J, Pepperkok R: 
Work flow for multiplexing siRNA assays by solid-phase reverse 
transfection in multiwell plates.  J Biomol Screen 2008, 13(7):575-580.
31. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang 
HE, Wettstein DA, Stray KM, Côté M, Rich RL, Myszka DG, Sundquist WI: 
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-
1 budding.  Cell 2001, 107(1):55-65.
32. Konvalinka J, Litterst MA, Welker R, Kottler H, Rippmann F, Heuser AM, 
Kräusslich HG: An active-site mutation in the human immunodeficiency 
virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-
mediated cytotoxicity without apparent effect on virus maturation and 
infectivity.  Journal of virology 1995, 69(11):7180-7186.
33. Börner K, Hermle J, Sommer C, Brown NP, Knapp B, Glass B, Kunkel J, 
Torralba G, Reymann J, Beil N, Beneke J, Pepperkok R, Schneider R, Ludwig 
T, Hausmann M, Hamprecht F, Erfle H, Kaderali L, Kräusslich HG, Lehmann 
MJ: From experimental setup to bioinformatics: an RNAi screening 
platform to identify host factors involved in HIV-1 replication.  
Biotechnology journal 2010, 5(1):39-49.
doi: 10.1186/1472-6750-10-32
Cite this article as: Hermle et al., A simple fluorescence based assay for 
quantification of human immunodeficiency virus particle release BMC Bio-
technology 2010, 10:32